On February 23, 2016, the markets were back to red again as the hopes of an oil freeze faded away along with the rise in oil prices. The S&P 500 and the Dow Jones Industrial Average fell by ~1.2% and 1.1%, respectively. The SPDR S&P Biotech ETF (XBI) gave up the most among the biotech ETFs on February 23. XBI fell by 4.8%. It went below the 20-day moving average price of $49.15 and closed at $48.24.
The above graph gives a summary of XBI, the SPDR S&P 500 ETF (SPY), and the top and bottom performers within XBI as of February 23, 2016.
Ziopharm rose by 14%
Ziopharm Oncology (ZIOP) rose by 14% on the announcement of “the publication of a study in Scientific Reports, a journal of the Nature Publishing Group, describing the genetic editing of human leukocyte antigen (HLA) in hematopoietic stem cells as a means of broadening the human application of these and other cell therapies.” Ziopharm closed at $7.27. It was trading above the 20-day and 50-day moving average prices of $5.6 and $6.7, respectively. Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV (price-to-book value) ratio of 10.1x. Ziopharm has a weight of 1.3% in XBI’s portfolio.
MiMedex (MDXG) bucked the trend as it announced its 2015 results. It reported revenue of $187.3 million for 2015—an increase of 58% over 2014. The net income stood at $29.4 million for 2015—a jump of 373% over 2014. MiMedex closed at $8.32 and gained 2.5% for the day. MiMedex has a weight of 0.6% in XBI’s portfolio.
On the other hand, Anacor Pharmaceuticals (ANAC) fell by 11.2% on profit-booking. It traded below the 20-day moving average price of $73. Anacor has a book value of $1.38 per share. With its current price, the stock was trading at a PBV ratio of ~48.7x. It has a weight of ~1.3% in XBI’s portfolio.